IPHA innate-pharma.com: Enterprise Value to EBITDA Ratio

Graphic logo of Innate Pharma (IPHA)

Innate Pharma S.A. (IPHA) relies on contract manufacturing capacities for drug production while its own laboratories operate at full capacity. The company's environmental strategy is based on bioethics and process energy efficiency. The share price history with an EV/EBITDA ratio of 0.00 is available below. Business innovations include synthesis automation and the use of AI in molecule creation, although the final stage of treatment remains with the physicians.

Innate Pharma, S.A. - IPHA Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for innate-pharma.com (IPHA)

- stock price and consensus target price:
Stock Quotes Innate Pharma, S.A.|IPHA - Average Forecast Price
- company stock capitalization data:
Market Valuation Innate Pharma S.A|IPHA - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Innate Pharma|IPHA - Book Valuation of Business|Market Value to Book Value Ratio innate-pharma.com|IPHA - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Innate Pharma S.A.|IPHA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Innate Pharma|IPHA - Company Aggregate Debts|Debt to Book Capitalization Ratio Innate Pharma S.A|IPHA - Company Long-Term Indebtedness|Company Short-Term Debt Innate Pharma|Quick Liquidity Indicator innate-pharma.com
- financial results and valuation multiples details:
IPHA - Annual Net Income|Future Profit Innate Pharma S.A.|IPHA - Market Price to Net Income Ratio|Forward P/E Multiple Innate Pharma S.A.|IPHA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Innate Pharma S.A|IPHA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Innate Pharma|IPHA - Earnings per share for the trailing year|Quarterly EPS earnings growth innate-pharma.com|IPHA - Earnings growth in current year|Net earnings per share growth forecast for next year Innate Pharma S.A.
Fundamental company analysis:IPHA (Innate Pharma, S.A.)
Original product of Innate Pharma SA

The monetization of Innate Pharma S.A. (IPHA) licenses in the targeted antibody segment requires a precise alignment of business value with its operating profit before taxes, depreciation, and amortization. This multiple excludes the impact of debt load, allowing for an assessment of real cash flow generation. By analyzing the company's valuation trend via EV/EBITDA, an investor separates speculative noise from fundamental value. This determines the stability of market capitalization relative to real assets.

Competitor analysis for Innate Pharma S.A.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation VCNX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx